CANF R&D to Revenue
Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares · R&D to Revenue
CANF R&D to Revenue
Latest reported1710.89%period ending
CANF Quarterly R&D/Revenue (494.73% → 1710.89%)
Latest values, visible window
High-resolution chart · PNG
CANF r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 1,710.8911% | |
| 1,710.8911% | |
| 1,802.4631% | |
| 1,802.4631% | |
| 1,501.9802% | |
| 1,501.9802% | |
| 802.2346% | |
| 802.2346% | |
| 912.9747% | |
| 912.9747% | |
| 817.4194% | |
| 662.7551% | |
| 691.8367% | |
| 1,051.5306% | |
| 1,245.6853% | |
| 998.0392% | |
| 711.7647% | |
| 888.2927% | |
| 1,520.098% | |
| 1,170.9163% | |
| 1,002.8% | |
| 880.4054% | |
| 1,930.6667% | |
| 948.3412% | |
| 1,609.3137% | |
| 1,904.5455% | |
| 2,062.5% | |
| 265.2778% | |
| 647.0437% | |
| 482.6087% | |
| 698.6159% | |
| 53.9369% | |
| 490.7407% | |
| 207.7532% | |
| 1,593.7947% | |
| 181.2439% | |
| 1,631.3092% | |
| 1,687.2257% | |
| -111,381.5113% | |
| 2,538.349% | |
| 2,770.0691% | |
| 1,905.1409% | |
| 5,245.3583% | |
| 1,389.0728% | |
| 1,301.5496% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 698.6512% | |
| 586.1023% | |
| 699.5573% | |
| 920.1822% | |
| 456.7143% | |
| 494.7262% |